Compare Eli Lilly And Co (LLY) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Snap On Incorporated — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Snap On Incorporated trades at $360.37 (market cap $18.56B). The key difference: Eli Lilly And Co is far larger — about 56× Snap On Incorporated's market cap, and Snap On Incorporated pays the higher dividend (2.72%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Snap On Incorporated for 37 Days on average.
| LLY | SNA | |
|---|---|---|
Market Cap | $1.04T | $18.56B |
Volume | 3,064,878 | 401,326 |
Sector | Health | Industrials |
52-Week High | $1.28K | $419.31 |
52-Week Low | $799.57 | $327.33 |
Typical Hold Time | 93 Days | 37 Days |
Enterprise Value | $1.09T | $18.20B |
Dividend Yield | 0.59% | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Snap-On Incorporated (SNA) trades at $358.88, down 0.28% on the day, with a bearish technical signal from moving averages and oscillators. The company reported solid fundamentals with a 19.6% net income margin and a 17.58% ROE for 2025. Recent earnings show a mix of beats and a miss, with Q3 2026 results pending. Analyst consensus is bullish with a $449 price target, but technical indicators suggest near-term caution amid institutional position adjustments.
The outlook for SNA is supported by strong profitability and analyst optimism, but faces headwinds from technical bearishness and valuation risks. Investment opportunity lies in execution of RCI initiatives and diagnostic segment growth, while risks include integration costs from acquisitions and softer OEM demand. The stock's premium valuation requires sustained earnings growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
